Navigation Links
Study Suggests Glucosamine Won't Ease Hip Arthritis
Date:2/18/2008

Research adds to debate on the supplement but doesn't settle it, one expert says,,,,

MONDAY, Feb. 18 (HealthDay News) -- Glucosamine sulfate, a popular dietary supplement purported to ease the pain and inflammation of arthritis, does not seem to help people with arthritis in their hips.

That's the conclusion of a study that compared the use of glucosamine to a placebo for the treatment of mild to moderate hip arthritis.

"For these patients with hip osteoarthritis, glucosamine sulfate does not seem to be an effective treatment on the basis of our results," said study author Rianne Rozendaal, a researcher at Erasmus Medical Center in Rotterdam, The Netherlands.

Not everyone is so certain that glucosamine isn't useful though.

"This study is not definitive. This is the first one specific on hip osteoarthritis, and only subgroups of patients improved. So, no confirmation, but no refuting either," said Dr. Johannes W.J. Bijlsma, the author of an accompanying editorial and chair of the department of rheumatology and clinical immunology at the University Medical Center Utrecht, in The Netherlands.

Results of the study appear in the Feb. 19 issue of the Annals of Internal Medicine.

As many as one in five Americans has been diagnosed with arthritis, according to the U.S. Centers for Disease Control and Prevention, and arthritis is the leading cause of disability in the United States.

While lifestyle interventions, such as exercising, can help prevent some of the disability associated with arthritis, few effective medical interventions are available. That may explain why people with arthritis turn to unproven remedies in the hope that these products might ease the pain in their aching joints.

Glucosamine sulfate is one such product, but clinical trials of the supplement have had mixed results. For every study that finds a benefit, it seems there's another that finds none. However, no studies had been done looking specifically at glucosamine's usefulness for arthritis of the hip, according to Rozendaal.

This double-blind randomized study included 222 people who had mild to moderate osteoarthritis of the hip. For two years, half the group took 1,500 milligrams of glucosamine daily and the other half took a placebo.

Pain and function levels were measured at the start of the study, and again every three months for two years. X-rays of the affected joint were taken at the start and end of the study to see if there was any improvement.

At the end of the study, the researchers found no evidence that glucosamine had any effect on pain or function, and they saw no improvement in the X-rays for people taking glucosamine. The researchers also conducted a small subgroup analysis on people with more severe arthritis, and found no benefit for this group either.

But an industry expert said the study contained what he called a "glaring error:" many of the patients had very low levels of daily pain.

"In other words, they don't have much room for improvement," said Dr. Jason Theodosakis, a consultant for the supplements industry and an assistant professor at the University of Arizona College of Medicine, Tucson.

"Patients with arthritis who have small amounts of pain -- not significant enough to inhibit sleeping, daily activities or work -- do fine without treatment. This is exemplified by the fact that only 19 percent of those in the placebo group were using daily medications," Theodosakis added. "I don't think conclusions should be drawn from the study."

Bijlsma agreed that the verdict is still out on glucosamine's effectiveness. Some studies have found that glucosamine is effective for knee arthritis, he noted, and because there are no good treatment options available for people with arthritis, Bijlsma said that taking glucosamine should remain an option for patients.

"I advise them to use it for three months; if they experience improvement, I advise them to continue. If there is no improvement, I advise them to stop. I'm aware that a lot of the osteoarthritis problems for patients are indeed symptoms [pain, stiffness] that are subjective, but patients can decide for themselves. In practice, between 60 and 70 percent of the patients continue this treatment for a more prolonged period of time," Bijlsma said.

More information

To learn more about osteoarthritis and available treatments, visit the U.S. National Institute of Arthritis and Musculoskeletal Diseases.



SOURCES: Rianne Rozendaal, M.Sc., researcher, Erasmus Medical Center, the Netherlands; Johannes W.J. Bijlsma, M.D., Ph.D., chairman, department of rheumatology and clinical immunology, University Medical Center Utrecht, the Netherlands; Jason Theodosakis, M.D., assistant professor, University of Arizona College of Medicine, Tucson; Feb. 19, 2008, Annals of Internal Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Scientists using laser light to detect potential diseases via breath samples, says new study
2. Major study links insurance status to advanced stage in multiple cancers
3. 7-year neck pain study sheds light on best care
4. PLC Systems Files IDE Supplement to Begin Pivotal Study of RenalGuard(TM) and Provides Update on Planned Development Timeline
5. UH researchers study Hispanic childrens activities, views on places to play
6. Study identifies which men are likely to have persistent prostate cancer
7. Research findings may lead to new ways to study and fight diabetes
8. Yale study offers insight into possible cause of lymphoma
9. New study shows extent of harmful human influences on global ecosystems
10. Drug-Coated Balloons Keep Leg Arteries Open: Study
11. Study: When it comes to physical activity, one size does not fit all
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Suggests Glucosamine Won't Ease Hip Arthritis
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: